10-K: Apimeds Pharmaceuticals US, Inc. Completes Merger, Expands into Digital Assets

Apimeds Pharmaceuticals US, Inc. announced the completion of its merger with MindWave Innovations Inc., integrating a digital asset treasury platform alongside its biopharmaceutical business.

Summary

• Apimeds Pharmaceuticals US, Inc. (APUS) completed a merger with MindWave Innovations Inc. on December 1, 2025, creating a dual-segment company with biopharmaceutical and digital asset operations.
• The company's biopharmaceutical segment focuses on the development of Apitox, a bee venom-based drug candidate for osteoarthritis and potentially multiple sclerosis.
• The digital asset segment, through MindWave, offers institutional Digital Asset Treasury (DAT) solutions, including secure Bitcoin treasury infrastructure and AI-supported yield programs.
• MindWave holds 1,000 Bitcoin as a reserve asset and plans to commercialize its DAT offerings for institutional clients.
• The company completed an Initial Public Offering (IPO) on May 12, 2025, raising approximately $11.6 million in net proceeds.
• A PIPE convertible note financing provided $10 million in gross proceeds, with $8 million held in restricted cash.
• The company reported a net loss of $6.0 million for the year ended December 31, 2025, compared to $1.4 million in the prior year, due to increased R&D and G&A expenses related to the IPO and merger.
• Substantial doubt exists about the company's ability to continue as a going concern, with plans to address liquidity through further financing and cost reductions.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as negative due to the significant net loss, material weakness in internal controls, and substantial doubt about the company's going concern status, despite the strategic diversification into digital assets.

Positives

• Successful completion of the merger with MindWave Innovations Inc., diversifying the company's business into digital assets.
• Completion of an Initial Public Offering (IPO) on May 12, 2025, providing capital and increased visibility.
• Acquisition of digital assets worth approximately $146.3 million at the acquisition date, including Bitcoin, USDT, and NILA Tokens.
• Secured $10 million in gross proceeds from the first tranche of a PIPE convertible note financing.
• Advancement of the biopharmaceutical pipeline with $1.6 million in R&D expenses for Apitox development.
• The company has a clear strategy for its biopharmaceutical product, Apitox, including plans for a Phase III trial.
• MindWave's DAT platform is designed to meet institutional demand for Bitcoin treasury solutions.
• The company has a strategy to engage third-party contractors for reimbursement, coding, and policy development for Apitox.

Negatives

• The company reported a net loss of $6.0 million for the year ended December 31, 2025, and has incurred recurring operating losses since inception.
• Substantial doubt exists about the company's ability to continue as a going concern.
• General and administrative expenses increased significantly to $10.2 million in 2025 from $1.3 million in 2024.
• The company has not yet generated revenue from its biopharmaceutical or digital asset operations.
• The company identified a material weakness in internal control over financial reporting due to insufficient segregation of duties.
• The company's biopharmaceutical development is still in the clinical stage, with no FDA approval for Apitox.
• The company's digital asset holdings are subject to significant price volatility and cybersecurity risks.
• The company has a limited number of employees (7 full-time and 1 consultant as of the report date).

Risks

• The company's ability to continue as a going concern is subject to substantial doubt due to recurring operating losses and negative cash flows.
• The company faces significant risks related to the development and regulatory approval of its biopharmaceutical product candidate, Apitox.
• The company's digital asset holdings are subject to extreme price volatility, cybersecurity threats, and evolving regulatory landscapes.
• The company has identified a material weakness in its internal control over financial reporting, which could impact the reliability of its financial statements.
• The company's success is dependent on its ability to raise additional capital through future financing activities, which is not guaranteed.
• The company's biopharmaceutical business is in the development stage and has not generated any revenue.
• The company's digital asset business is new and subject to the inherent risks and uncertainties of the cryptocurrency market.
• The company's reliance on third-party manufacturers and service providers introduces operational and supply chain risks.
• The company's ability to obtain FDA approval for Apitox is subject to rigorous clinical trial requirements and regulatory review processes.
• The company's digital asset operations are subject to evolving and uncertain regulatory frameworks in the United States and globally.

Future Outlook

The company expects to continue incurring significant operating losses as it advances the clinical development of Apitox and builds its operational infrastructure. Future capital requirements are expected to be funded through the remaining tranches of the PIPE convertible note facility, potential NILA Token sales, and additional equity or debt financing. Management believes these sources will fund operations over the next twelve months, but there is no assurance of success.

Management Comments

• Fiscal year 2025 was a transformative year for the Company.
• The Merger fundamentally changed the scale and composition of our balance sheet, adding approximately $145.3 million in identifiable net assets, primarily digital assets.
• Our ability to continue as a going concern depends on our ability to raise additional capital and execute our operational plans.
• Management believes that the remaining available tranches under the Securities Purchase Agreement, combined with continued NILA Token sales for USDT proceeds and potential additional equity or debt financing, represent the primary sources of capital to fund operations over the next twelve months.

Industry Context

StockSavvy.ai notes that Apimeds Pharmaceuticals US, Inc. is navigating a complex dual-segment strategy, combining the high-risk, high-reward biopharmaceutical sector with the volatile and rapidly evolving digital asset market. The company's focus on Apitox for osteoarthritis addresses a large market with significant unmet needs, while its digital asset arm, MindWave, aims to capitalize on institutional adoption of Bitcoin treasury solutions. The success of both segments will depend heavily on regulatory navigation, clinical trial outcomes, and market acceptance of digital assets.

Comparison to Industry Standards

• The company's biopharmaceutical development for Apitox is in the clinical stage, with a Phase III trial planned for knee OA. This aligns with industry standards for drug development, but the success of the trial and subsequent FDA approval are critical.
• The digital asset treasury solutions offered by MindWave are emerging in the market. While institutional adoption of Bitcoin is growing, the regulatory landscape remains uncertain, and companies like MicroStrategy and Tesla have also explored Bitcoin as a treasury reserve asset, though with varying degrees of success and public disclosure.
• The company's net loss of $6.0 million on zero revenue is common for development-stage biopharmaceutical companies and early-stage digital asset ventures. However, the substantial increase in G&A expenses post-IPO and merger warrants close monitoring.
• The company's reliance on external financing, including convertible notes and potential future equity raises, is typical for companies in these sectors, but the 'going concern' note highlights the critical need for successful capital generation.

Legal Proceedings

• The company entered into a Confidential Settlement and Mutual Release Agreement with Inscobee Inc. and Apimeds Inc. to resolve all outstanding disputes arising from the Merger Agreement and related transactions.
• The company entered into a Forbearance Agreement with Alto Opportunity Master Fund, SPC regarding a senior convertible note, agreeing to forbear from exercising rights related to certain events of default through June 30, 2026.

Related Party Transactions

• The company has a business agreement with Apimeds Korea, a principal stockholder, granting a license for Apitox in the US in exchange for a 5% royalty on earnings before interest and taxes.
• The company entered into an assignment agreement with Apimeds Korea and Dr. Christopher Kim related to intellectual property for Apitoxin.
• The company entered into a patent license agreement with Dr. Christopher Kim, which has since expired.
• Apimeds Korea provided funding to the company through business establishment agreements totaling $1,000,000.
• The company issued convertible promissory notes to Apimeds Korea (assigned to Inscobee, Inc.) and related party notes payable to Inscobee Inc. and an officer.
• The company received an advance payable to its CEO of $12,000 as of December 31, 2025.

Stakeholder Impact

• Shareholders may experience dilution due to future equity or debt financing and potential conversion of convertible notes.
• The company's going concern status and financial performance will directly impact shareholder value.
• Employees may face uncertainty due to the company's financial position and the need for cost reductions.
• Creditors and noteholders are exposed to the company's ability to meet its financial obligations, as evidenced by the forbearance agreement.
• Partners and suppliers may face payment risks given the company's liquidity challenges.

Next Steps

• Advance Apitox through clinical development and pursue FDA approval.
• Scale the institutional DAT platform and onboard initial institutional clients.
• Progress AI-supported, risk-managed yield programs.
• Stand up enterprise validator services.
• Advance development of ClimateTech, AdTech, and InsurTech verticals.
• Continue to raise capital to fund operations and development.
• Address the material weakness in internal controls over financial reporting.

Key Dates

Recommendation

The company's significant net loss, material weakness in internal controls, and substantial doubt about its going concern status, coupled with the lack of revenue and early-stage development of its core products, present considerable risks. While the diversification into digital assets offers potential upside, the current financial instability and operational challenges outweigh the speculative growth prospects.

Keywords

Apimeds Pharmaceuticals, Form 10-K, SEC Filing, Annual Report, Apitox, Osteoarthritis, Multiple Sclerosis, Biopharmaceutical, MindWave Innovations, Digital Asset Treasury, Bitcoin, NILA Token, IPO, Convertible Notes, Going Concern, Clinical Trials, FDA Approval